Survival Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients Treated with Sorafenib
Jeong-Han KIM; Hyung-Min YU; Yong HWANG; Soon-Young KO; Won-Hyeok CHOE; So-Young KWON.
Journal of Liver Cancer
; : 23-30, 2016.
Artículo en Inglés | WPRIM | ID: wpr-194401
Documentos relacionados
Impact of hepatic inflammation and fibrosis on the recurrence and long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after hepatectomy.
HBV infection may reduce the risk of metachronous liver metastasis in postoperative pathological stage 2 colorectal cancer.
Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Primary non-response to antiviral therapy affects the prognosis of hepatitis B virus-related hepatocellular carcinoma.
The Role of Circulating Free DNA and MicroRNA in Non-Invasive Diagnosis of HBV- and HCV-Related Hepatocellular Carcinoma.
Clinical prognosis and related molecular features of hepatitis B-associated adolescent and young adult hepatocellular carcinoma.
A Clinic Study on Long-term Efficacy and Safety of Autologous Peripheral Blood Stem Cell Transplantation in Patients with Decompensated Hepatitis B Cirrhosis.
Effects of Clonorchis sinensis combined with Hepatitis B virus infection on the prognosis of patients with Hepatocellular Carcinoma following Hepatectomy.
Hepatitis B Virus DNA-Level Change is Associated With Tumor Recurrence in Patients With Resected Hepatitis B Virus Hepatocellular Carcinoma.
Pre-operative gamma-glutamyl transferase levels predict outcomes in hepatitis B-related hepatocellular carcinoma after curative resection.